P3 Health Partners (PIII) Stock Surges Over 42% After Hours: Here's Why

P3 Health Partners Inc. ( PIII ) shares surged 42.68% to $5.75 in after-hours trading on Thursday after the Nevada-based population health management company posted first-quarter 2026 results, reporting earnings per share of negative $1.72, beating analyst estimates of negative $3.28 by 47.56%. This marks a stark turnaround from the fourth quarter reported in March, when EPS was negative $23.02, missing estimates by 182.11%. Sharp Reversal From Year-Ago Loss P3 Health’s revenue for the quarter ended Mar. 31 rose 4% year-over-year to $386 million, while per-member revenue surged 14%, driven by contract restructuring and rate improvements. Adjusted EBITDA came in at $25.8 million, or $81 per member per month. Net income of the company was $3 million compared to a $44.2 million net loss in the year-ago quarter. Raised Guidance CEO Dr. Aric Coffman credited “two years of deliberate work” in contract restructuring, network concentration, and operational redesign for the turnaround, raising the full-year 2026 adjusted EBITDA guidance midpoint to $40 million. P3 Health ( PIII ) provided full-year 2026 guidance calling for total revenues of $1.50 billion to $1.65 billion and adjusted EBITDA of $20 million to $60 million. Trading Metrics, Technical Analysis P3 Health ( PIII ) has a market capitalization of $29.17 million, a 52-week high of $11.30 and a 52-week low of $1.52. The Relative Strength Index (RSI) of PIII stands at 71.93. The small-cap stock has dropped 51.45% over the past 12 months. PIII is currently trading at about 26% of its 52-week range, placing it closer to its 52-week low than its high. Price Action: P3 Health ( PIII ) closed the regular session up 12.89% at $4.03, according to Benzinga Pro. Benzinga’s Edge Stock Rankings indicate that PIII is experiencing long-term consolidation along with medium and short-term upward movement. Photo Courtesy: abunuh051992 on Shutterstock.com Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Read Also: HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session